VR Logo

Albireo Pharma Inc. (ALBO) download report


Healthcare | Biotechnology & Pharma Research

Albireo Pharma Inc. (ALBO) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders.

IPO Date: 11-May-2007

CEO, Pres & Director: Mr. Ronald H. W. Cooper

CFO & Treasurer: Mr. Simon Nicolas Reade Harford

Listing: NASDAQ: ALBO

Country: United States

Headquarters: Boston, MA

Website: https://www.albireopharma.com

Key Facts

Market cap: $370.58 Mln

Revenue (TTM): $45.45 Mln

Earnings (TTM): $-32.73 Mln

Cash: $216.66 Mln

Total Debt: $10.08 Mln

Insider's Holding: 0.64%

Liquidity: Low

52 Week range: $17.83 - 37.86

Shares outstanding: 19,576,300

10 Years Aggregate:

  • CFO: $-400.60 Mln
  • EBITDA: $-361.81 Mln
  • Net Profit: $-361.61 Mln

Stock Performance

Time Period Albireo Pharma (ALBO) S&P BSE Sensex S&P Small-Cap 600
YTD-9.27-9.18-18.78
1 month2.08-4.78-8.00
3 months-29.17-9.66-13.65
1 Year-39.940.81-17.19
3 Years-13.1410.336.10
5 Years0.5111.345.87
10 Years-12.1811.749.84
As on 01-Jul-2022
Year Albireo Pharma (ALBO) S&P Small-Cap 600 S&P BSE Sensex
2021-37.9125.2721.99
202047.569.5715.75
20193.6320.8614.38
2018-4.16-9.705.87
201744.3911.7327.91
201672.5024.741.95
2015-74.24-3.36-5.03